News from the debiopharm group A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jan 09, 2013, 04:00 ET

Spinomix Closes a $ 3 Million Financing Round Led by Debiopharm Group

Debiopharm Group™ (Debiopharm) and Spinomix SA, a Swiss company advancing molecular diagnostic technologies, announced the closing of a...

Jan 08, 2013, 01:00 ET

Chugai and Debiopharm Group Announce an Exclusive License Agreement for Anti-Cancer Agent, FF284 (Debio 1347)

Chugai Pharmaceutical Co., Ltd. ("Chugai") and Debiopharm GroupTM ("Debiopharm") announced today that on December 17, 2012, they entered into a...

Dec 07, 2012, 03:00 ET

Dr. Reddy's Launches Debiopharm's Pamorelin® LA in India for the Treatment of Locally Advanced or Metastatic, Hormone-Dependent Prostate Cancer

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription...

Sep 21, 2012, 03:00 ET

The Japanese Cancer Association and Debiopharm Group Present Doctors Oshima and Tanaka with the 2012 'JCA-Mauvernay Award' for their Innovative and Outstanding Cancer Research

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription...

Aug 27, 2012, 03:00 ET

Debiopharm Announces First Patient Enrolled in Phase III Study for the Rare Disease Central Precocious Puberty

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription...

Jul 24, 2012, 03:00 ET

Debiopharm Group™ - First Patient Treated in Phase III Study With Subcutaneous Administration of Debio 8206 for Treatment of Advanced Prostate Cancer

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription...

Jun 18, 2012, 03:00 ET
Jun 06, 2012, 04:00 ET

Debiopharm Presented Results at the ASCO 2012 Annual Meeting - Results of Phase I Study With Debio 0932, an Oral HSP90 Inhibitor in Patients With Solid Tumours

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription...

May 15, 2012, 03:00 ET

Debiopharm and Vifor Pharma Sign an Exclusive Agreement for the Distribution and Commercialization of Pamorelin®LA in Switzerland - A Drug Treatment for Prostate Cancer and Endometriosis

Debiopharm Group™ (Debiopharm) and Vifor Pharma announce the signing of an exclusive agreement covering the distribution and...

Feb 16, 2012, 07:00 ET

Debiopharm and Curis Announce Initiation of Phase Ib Expansion Study of HSP90 Inhibitor Debio 0932

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, and Debiopharm...

Nov 09, 2011, 05:07 ET

Augurix Diagnostics Receives the 2011 'Debiopharm /Valais Award' for its Point-of-care Diagnostic Test for the Early Detection of Celiac Disease

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group with a focus on drug development and companion diagnostics,...

Oct 05, 2011, 04:00 ET

The Japanese Cancer Association and Debiopharm Group™ Present Doctors Arakawa and Kurokawa With the 2011 'JCA-Mauvernay Award' for Their Innovative and Outstanding Research in the Field of Cancer

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group with a focus on drug development and companion diagnostics,...

Sep 08, 2011, 04:00 ET

Debiopharm Group™ Presents the 'Debiopharm Group™ Life Sciences Award 2011' and two 'Junior Debiopharm Group™ Awards 2011' at the ISREC 2011 Life Sciences Symposium

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group with a focus on drug development and companion diagnostics,...

Jul 26, 2011, 03:00 ET

INC Research and Debiopharm Group(TM) Announce Strategic Partnership

INC Research, LLC, a therapeutically focused contract research organisation (CRO) with a trusted process for delivering reliable results, and...

Jul 14, 2011, 04:45 ET

Continuity as Debiopharm Group™ Management Moves Forward

  Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of...

May 04, 2011, 03:00 ET

Debiopharm and Yale Announce an Exclusive License Agreement for the Development and Commercialization of Debio 1036, a First-in-Class Inhibitor for Autoimmune and Inflammatory Diseases

Debiopharm Group(TM) (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly...

Apr 14, 2011, 03:00 ET

Debiopharm and Aurigene Sign Agreement for the Development and Commercialisation of Debio 1142, a Novel Inhibitor of an Undisclosed Oncology Pathway

LAUSANNE, Switzerland and BANGALORE, India, April 14, 2011 /PRNewswire/ -- Debiopharm Group(TM) (Debiopharm), a global biopharmaceutical...

Jan 18, 2011, 03:00 ET

Diagnoplex Closes an Extension of its Series A Financing With a Substantial Investment by Debiopharm Group(TM)

Diagnoplex SA, a developer of molecular diagnostics for colon cancer and Debiopharm Group(TM) announced today that Diagnoplex has closed a series A...

Dec 01, 2010, 10:00 ET

Frost & Sullivan Presents Debiopharm Group(TM) with "European Biopharmaceuticals Company of the Year Award"

Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative...